Kim Eun-Jin, Go Ho-Yeon, Sung Hyun-Kyung
Department of Pediatrics of Korean Medicine, Korean Medicine Hospital, Dongguk University Bundang Medical Center, Seongnam-si 13601, Republic of Korea.
Department of Korean Internal Medicine, College of Korean Medicine, Semyung University, Jecheon-si 27136, Republic of Korea.
Microorganisms. 2025 Jun 20;13(7):1441. doi: 10.3390/microorganisms13071441.
Neonatal hyperbilirubinemia (NH), which commonly presents as jaundice, affects approximately 60% of term infants and up to 80% of preterm infants within the first week of life. This study aimed to assess the efficacy and safety of () supplementation combined with phototherapy versus phototherapy alone for the treatment of NH. A systematic search of 11 databases (English, Chinese, and Korean) was conducted from 18 April 2025. Eligible randomized controlled trials (RCTs) compared plus phototherapy with phototherapy alone. Meta-analyses were performed using the mean difference (MD), standardized mean difference (SMD), and risk ratio (RR) with a 95% confidence interval (CIs). Evidence quality was evaluated using the GRADE approach. This review included 20 RCTs of 1054 neonates. Compared to phototherapy alone, supplementation significantly reduced total bilirubin (SMD = -1.54, 95% CI: -2.21 to -0.86), indirect bilirubin (SMD = -2.03, 95% CI: -2.98 to -1.07), and time to jaundice resolution (MD = -1.20 days, 95% CI: -1.66 to -0.75), and was associated with fewer adverse events (RR = 0.40, 95% CI: 0.30 to 0.55) (all < 0.0001). These findings suggest that may have potential as a supportive adjunct therapy for neonatal hyperbilirubinemia. However, further studies are needed to confirm its efficacy and safety. The protocol is registered in PROSPERO (CRD420251031376).
新生儿高胆红素血症（NH）通常表现为黄疸，在出生后第一周内影响约60%的足月儿和高达80%的早产儿。本研究旨在评估（）补充剂联合光疗与单纯光疗治疗NH的疗效和安全性。从2025年4月18日开始对11个数据库（英文、中文和韩文）进行了系统检索。符合条件的随机对照试验（RCT）比较了（）加光疗与单纯光疗。使用平均差（MD）、标准化平均差（SMD）和风险比（RR）及95%置信区间（CI）进行荟萃分析。采用GRADE方法评估证据质量。本综述纳入了1054例新生儿的20项RCT。与单纯光疗相比，（）补充剂显著降低了总胆红素（SMD = -1.54，95%CI：-2.21至-0.86）、间接胆红素（SMD = -2.03，95%CI：-2.98至-1.07）以及黄疸消退时间（MD = -1.20天，95%CI：-1.66至-0.75），且不良事件较少（RR = 0.40，95%CI：0.30至0.55）（所有P < 0.0001）。这些发现表明，（）可能有作为新生儿高胆红素血症辅助支持治疗的潜力。然而，需要进一步研究来证实其疗效和安全性。该方案已在PROSPERO注册（CRD420251031376）。
